Home>>Signaling Pathways>> Others>>Pamabrom

Pamabrom

Catalog No.GC36845

Pamabron is a common over-the-counter diuretic used for relief of menstrual-associated symptoms.

Products are for research use only. Not for human use. We do not sell to patients.

Pamabrom Chemical Structure

Cas No.: 606-04-2

Size Price Stock Qty
10mM (in 1mL DMSO)
$110.00
In stock
100mg
$100.00
In stock
500mg
$200.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Pamabron is a common over-the-counter diuretic used for relief of menstrual-associated symptoms. The active diuretic ingredient in pamabrom is 8-bromotheophylline. Pamabrom is available in combination with acetaminophen (paracetamol) for various conditions such as back pain and menstrual relief. The acetaminophen helps reduce menstrual pains and the pamabrom reduces associated bloating.

[1]. Ortiz MI, Rangel-Flores E, Carrillo-AlarcÓn LC, et al. Prevalence and impact of primary dysmenorrhea among Mexican high school students. Int J Gynaecol Obstet. 2009 Dec;107(3):240-3. [2]. Swanson JK, English JC 3rd. Serum sickness-like reaction to Pamabrom. J Drugs Dermatol. 2006 Mar;5(3):284-6. [3]. Di Girolamo G, SÁnchez AJ, De Los Santos AR, et al. Is acetaminophen, and its combination with pamabrom, an effective therapeutic option in primary dysmenorrhoea• Expert Opin Pharmacother. 2004 Mar;5(3):561-70. [4]. Pamabrom

Reviews

Review for Pamabrom

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pamabrom

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.